Скачать с ютуб This Drug Synthesis is Literally Breathtaking | Medicinal Chemistry & Organic Synthesis в хорошем качестве

This Drug Synthesis is Literally Breathtaking | Medicinal Chemistry & Organic Synthesis

This molecule might look like any other 'flat drug' - but there's a mystery hidden behind its synthesis! Coupled with the fact that it showed promise in asthma due to its novel mechanism, you could say that it's breath-taking (actually more like breath-giving, but I figured no one will understand this). Watch this video to learn more about organic synthesis, drug development and more! 00:00 A breath-taking synthesis 00:23 Structure of our target molecule 01:37 Intro to PI3K enzymes and inhibitor drugs 03:41 Levels of chemistry sophistication 05:09 Retrosynthesis of AZD8154 and overview 05:57 Forward synthesis # 1 07:26 What was the problem? 08:19 Forward synthesis # 2 11:10 How legit is the solution? 12:03 FDA stance on PI3K inhibitors, and conclusion   / totalsynthesis   🚀 Thanks to all channel supporters!!!   / totalsynthesis_official   👉 Follow me on Instagram for updates on random research, mechanism quizzes and interesting news! https://www.total-synthesis.com Disclaimer - This channel does not provide medical advice! No information on this channel is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of information on Youtube. Key references: - Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of Asthma | J. Med. Chem. 2021, 64, 8053 - Class I Phosphoinositide 3-Kinase PIK3CA/p110α and PIK3CB/p110β Isoforms in Endometrial Cancer | Int. J. Mol. Sci. 2018, 19, 3931 - The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review | Cancers 2021, 13, 3949 - Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-γ Inhibitors | J. Med. Chem. 2018, 61, 5435 - An Intramolecular Diels–Alder Approach to the Isoindolinone Core of AZD8154 | doi.org/10.1021/acs.oprd.3c00507 - Selection and Development of the Manufacturing Route for EP1 Antagonist GSK269984B | Org. Process Res. Dev. 2010, 14, 820 - Characterisation of pharmacokinetics, safety and tolerability in a first-in-human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory disease | Br J Clin Pharmacol. 2022, 88, 260 - Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib | Drug Des Devel Ther 2018, 12, 2577